The EDC is live today — see what ships now
All studies
NCT07229313From ClinicalTrials.govRecruiting

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

  • Advance Solid Tumors

At a glance

Phase
Phase 1
Study type
Interventional
Sponsor
Kivu Bioscience Inc.
Enrolment target
76
Started
13 November 2025
Main results due
31 March 2028
Study sites
7
Registry updated
24 September 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Male or female ≥18 years of age
* No therapy of proven efficacy exists for the tumor
* Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.
* Adequate bone marrow, kidney, and liver function
* Measurable disease using RECIST v1.1
* ECOG 0 or 1
* Life expectancy ≥ 3 months

Exclusion Criteria:

* Prior treatment with any ADC with topoisomerase 1 inhibitor payload
* Any PTK7 - targeted therapy
* Uncontrolled cardiovascular disease
* Active Hepatitis B, Hepatitis C, or HIV infection
* History of interstitial lung disease
* Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.

What this study is about

In the sponsor’s own words, from the registry.

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Study sites(7)

  • Kivu Trial Site

    Santa Monica, California, United States

    Recruiting

  • Kivu Trial Site

    New Have, Connecticut, United States

    Recruiting

  • Kivu Trial Site

    Camperdown, New South Wales, Australia

    Recruiting

  • Kivu Trial Site

    Sydney, New South Wales, Australia

    Recruiting

  • Kivu Trial Site

    Brisbane, Queensland, Australia

    Recruiting

  • Kivu Trial Site

    Adelaide, South Australia, Australia

    Recruiting

  • Kivu Trial Site

    Geelong, Victoria, Australia

    Recruiting

Showing 7 of 7 sites. 7 of the 7 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07229313. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | Trialion